Inotek Pharmaceuticals Corp (NASDAQ:ITEK) target price increased to $22.00, reported today by HC Wainwright
- Updated: September 20, 2016
In a report issued 9/20/2016 HC Wainwright raised the target price of Inotek Pharmaceuticals Corp (NASDAQ:ITEK) from $0 to $22 reporting a possible upside of 1.60%.
Previously on 7/27/2015, Canaccord Genuity reported about Inotek Pharmaceuticals Corp(NASDAQ:ITEK) raised the target price from $11.00 to $30.00. At the time, this indicated a possible upside of 0.70%.
Yesterday Inotek Pharmaceuticals Corp (NASDAQ:ITEK) traded 1.93% higher at $8.47. The company’s 50-day moving average is $7.08 and its 200-day moving average is $8.10. The last close is up 4.50% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. 282,957 shares of the stock traded, up from ann avg. volume of 273,931.
See Graph Below:
Inotek Pharmaceuticals Corp has a one-year low of $5.81 and a one-year high of $14.07. Inotek Pharmaceuticals Corp’s total market value is currently $0.0.
General Company Details For Inotek Pharmaceuticals Corp (NASDAQ:ITEK)
Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism. The Company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye’s trabecular meshwork (TM). Its product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination (FDC), and of trabodenoson with latanoprost given once-daily (QD). The Company is evaluating the potential of trabodenoson to slow the loss of vision associated with glaucoma and degenerative retinal diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.